AGP Picks
View all

PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month

News originally published by

GlobeNewswire

Feature examines how survival data, FDA decisions and new diagnostics are putting clinical endpoints in focus for small-cap lung cancer companies

Chest X-ray beside the PRISM MarketView logo, a purple awareness ribbon and the text “Lung Cancer Awareness Month: Survival Data in Focus.”

NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- PRISM MarketView, a financial media platform covering small-cap public companies through 27 thematic indexes, today published a Lung Cancer Awareness Month feature on seven small-cap companies developing therapies and diagnostics for lung cancer, the leading cause of cancer death in the U.S.

The feature follows the FDA's decision not to approve a PD-1xVEGF bispecific antibody in EGFR-mutated lung cancer after the agency concluded the data could not establish effectiveness without a statistically significant survival benefit. The decision has put clinical endpoints in focus for smaller developers working in the disease.

Candel Therapeutics (NASDAQ: CADL) and MAIA Biotechnology (NYSE American: MAIA) are running Phase 3 trials that use overall survival as their primary endpoint. Cullinan Therapeutics (NASDAQ: CGEM) and partner Taiho Oncology are awaiting an FDA decision on zipalertinib, with a target action date of February 27, 2027. Crescent Biopharma (NASDAQ: CBIO) expects proof-of-concept data for its PD-1xVEGF bispecific CR-001 in the first quarter of 2027, and Tango Therapeutics (NASDAQ: TNGX) plans to disclose lung cancer data for vopimetostat in January 2027.

Personalis (NASDAQ: PSNL) secured Medicare coverage for its NeXT Personal residual disease test in stage I to III non-small cell lung cancer, and bioAffinity Technologies (NASDAQ: BIAF) is extending its CyPath Lung test to monitoring survivors after treatment.

Read the full article on PRISM MarketView: https://prismmarketview.com/fda-rejection-of-summits-lung-cancer-drug-puts-survival-data-at-the-center-for-small-caps/

About PRISM MarketView

PRISM MarketView is a financial media and index publishing platform for investors seeking small-cap opportunities. Since 2020, PRISM has covered emerging growth companies through daily news, analysis and 27 thematic small-cap indexes spanning biotech, medtech, AI, energy and more. Learn more at prismmarketview.com.

Follow PRISM MarketView on X, LinkedIn, Instagram, TikTok and YouTube.

PRISM MarketView does not provide investment advice.

Media Contact
info@prismmarketview.com
646-863-6341

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b1585272-bd54-4c1f-9906-10b0b20882a4


Primary Logo

Lung Cancer Awareness Month: Survival Data in Focus

PRISM MarketView highlights small-cap lung cancer developers for Lung Cancer Awareness Month, as survival data takes center stage after the FDA’s ivonescimab decision.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa Finance Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.